Antineutrophil Cytoplasmic Antibodies Vasculitis Panel, Serum
Use
Evaluating patients with clinical features of anti-neutrophil cytoplasmic antibody-associated vasculitis, specifically granulomatosis with polyangiitis, microscopic polyangiitis, and eosinophilic granulomatosis with polyangiitis. Patients with suspected ANCA-associated vasculitis should be evaluated for the presence of PR3-ANCA, MPO-ANCA and ANCA by IIF. ANCA by IIF should then be used in cases where there is a high degree of suspicion for GPA or MPA, but the PR3-ANCA and MPO-ANCA testing is negative. ANCA-associated vasculitides are characterized by a pauci-immune inflammation within the walls of small blood vessels.
Special Instructions
Not provided.
Limitations
A positive result for proteinase 3 or myeloperoxidase anti-neutrophil cytoplasmic antibodies is not diagnostic for any ANCA-associated vasculitis and must be interpreted in the clinical context of the patient. Negative results for PR3-ANCA, MPO-ANCA, and ANCA by IIF do not exclude the possibility of ANCA-associated vasculitis. Antibodies specific for antigens other than PR3 and MPO may lead to nuclear, perinuclear, or cytoplasmic staining on ethanol-fixed neutrophils.
FDA ApprovedNew York Approved
Methodology
Immunoassay (Multiplex Protein Panel)
Biomarkers
LOINC Codes
- 90230-4 - MPO IgG & PR3 Ab.IgG Panel Ser
- 48404-8 - Myeloperoxidase IgG Ser-aCnc
- 74106-6 - Proteinase3 IgG SerPl IA-aCnc
Result Turnaround Time
3-4 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL
Minimum Volume
0.5 mL
Container
Plastic vial
Collection Instructions
Centrifuge and aliquot serum into a plastic vial.
Causes for Rejection
Gross hemolysis, Gross lipemia
Stability Requirements
| Temperature | Period |
|---|---|
| Refrigerated | 21 days |
| Frozen | 21 days |